StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies

Inclusion Criteria: * Must have a partially HLA matched UCB unit with a pre-cryopreserved TNC dose \>2.5 x 107 per kilogram recipient weight. HLA matching is initially based on 4 of 6 HLA-A and B (at low or intermediate resolution by molecular typing) and DRB1 (at high resolution by molecular typing). * Eligible Diseases * Acute myelogenous leukemia (AML) at the following stages: * Intermediate to high risk leukemia in first complete remission (CR1) based on institutional criteria. * Any second or subsequent CR. * Secondary AML with prior malignancy that has been in remission for at least 12 months. * Acute lymphocytic leukemia (ALL) at the following stages: * High risk first remission. 1. Ph+ ALL, or 2. MLL rearrangement with slow early response at Day 14, or 3. Hypodiploidy (\< 44 chromosomes or DNA index \< 0.81), or 4. End of induction M3 bone marrow, or 5. End of induction M2 with M2-3 at Day 42. * High risk second CR based on institutional criteria (eg, for children, bone marrow relapse \<36 months from induction or T-lineage bone marrow relapse or very early isolated central nervous system (CNS) relapse \<6 months from diagnosis, or slow re-induction (stage M2-3 at day 28 after induction) regardless of length remission. * Any third or subsequent CR. * Biphenotypic/undifferentiated leukemia in CR * Chronic myelogenous leukemia (CML) excluding refractory blast crisis * Myelodysplasia (MDS) IPSS Int-2 or High risk (i.e. RAEB, RAEBt) or refractory anemia * Other Inclusion Criteria * Karnofsky score \>70% (16 years and older) or a Lansky play score \>70 (children \<16 years) - appendix II * Adequate organ function defined as: * Renal: Serum creatinine within normal range for age, or if serum creatinine outside normal range for age, then renal function (creatinine clearance or GFR) \>70 mL/min/1.73 m2. * Hepatic: Bilirubin ≤2.5 x mg/dL; AST, ALT, alkaline phosphatase \<5 x upper limit of normal, * Pulmonary function: DLCO, FEV1, FEC (diffusion capacity) \>50% of predicted (corrected for hemoglobin); if unable to perform pulmonary function tests, then normal O2 saturation on room air. * Cardiac: Left ventricular ejection fraction at rest must be \>45% * Available 'back-up' HSPC graft (e.g, second partially HLA matched UCB unit, haploidentical related donor). * Voluntary written consent signed (adult or parental) before performance of any study-related procedure not part of normal medical care Exclusion Criteria: * Pregnant or breast feeding. The agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk. Females of childbearing potential must have a blood test or urine study within 14 days prior to study enrollment to rule out pregnancy. * Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology. * Active bacterial, viral or fungal infection (currently taking medication and progression of clinical symptoms). * Prior autologous or allogeneic transplant within past 12 months. * Other active malignancy. * Inability to receive TBI 1320 cGy (e.g., extensive prior therapy including \>12 months alkylator therapy or \>6 months alkylator therapy with extensive radiation. Or prior Y-90 ibritumomab (Zevalin) or I-131 tostumomab (Bexxar), as part of their salvage therapy.